Journal articleLancet2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
- Journal
- Lancet
- Published
- 11 September 2023
- Citations
- 371
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 7
- Builds on itA Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxalipl… NCT04083235↗
- BackgroundFecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metas… NCT07854977↗
- BackgroundNALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer NCT07595172↗
- BackgroundStereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer NCT07173387↗
- BackgroundOnvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer NCT06736717↗
- BackgroundOxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (… NCT06538623↗
- BackgroundLosartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer NCT04106856↗